Clicky

Hutchison China MediTech Limited(HCM) News

Date Title
Oct 1 HUTCHMED (China) (LON:HCM) shareholders are up 17% this past week, but still in the red over the last three years
Sep 26 Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Aug 30 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China
Aug 28 HUTCHMED (China) Limited (HCM): A Cheap Pharmaceutical Stock to Buy According to Short Sellers
Aug 21 HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
Jul 29 HUTCHMED (China) Limited's (LON:HCM) last week's 6.4% decline must have disappointed private equity firms who have a significant stake
Jun 26 HUTCHMED to Announce 2024 Half-Year Financial Results
Jun 24 Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
Jun 21 HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Jun 7 HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
May 24 HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
May 17 HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
May 17 HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
May 14 HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
May 14 HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
May 8 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
Apr 26 HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
Apr 24 HUTCHMED (China) (LON:HCM) shareholders are up 8.2% this past week, but still in the red over the last five years
Apr 5 HUTCHMED Highlights Data to be Presented at AACR Congress 2024
Apr 2 HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status